Experienced in Diffuse Large B-Cell Lymphoma (DLBCL)

Geoff Chong

Heidelberg, VIC, AU 
Experienced in Diffuse Large B-Cell Lymphoma (DLBCL)
Heidelberg, VIC, AU 
OverviewLocationsClinical Research

Overview

Geoff Chong practices in Heidelberg, Australia. Mr. Chong is rated as an Experienced expert by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Follicular Lymphoma, Febrile Neutropenia, Non-Hodgkin Lymphoma, and B-Cell Lymphoma.

His clinical research consists of co-authoring 23 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article and participated in 1 clinical trial in the study of Diffuse Large B-Cell Lymphoma (DLBCL).

Gender
Male

Locations

Heidelberg, VIC, Australia
Other Locations
Newton, SA, Australia
Grampians Health Ballarat
Ballarat, VIC, Australia
Northern Health
Epping, NSW, Australia
Melbourne, VIC, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy
Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy
Enrollment Status: Active_not_recruiting
Publish Date: March 21, 2025
Intervention Type: Drug, Radiation
Study Drugs: Obinutuzumab, Atezolizumab
Study Phase: Phase 2
Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse Large B Cell Lymphoma (DLBCL): The AvR-CHOP Study
Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse Large B Cell Lymphoma (DLBCL): The AvR-CHOP Study
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2024
Intervention Type: Drug
Study Drug: Avelumab
Study Phase: Early Phase 1
A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction
A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction
Enrollment Status: Completed
Publish Date: June 09, 2022
Intervention Type: Drug, Other
Study Phase: Phase 3
View 2 Less Clinical Trials

23 Total Publications

Refinement of primary central nervous system lymphoma prognostication and response assessment using 3-dimensional MRI.
Refinement of primary central nervous system lymphoma prognostication and response assessment using 3-dimensional MRI.
Journal: Neuro-oncology advances
Published: June 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Chong's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile